Lincoln Pharma allocates approximately Rs 30 cr for expansion of cephalosporin product portfolio, Health News, ET HealthWorld

New Delhi: Pharmaceutical company Lincoln Pharmaceuticals said on Tuesday it had earmarked an investment of around Rs 30 crore to expand its portfolio of cephalosporin products and plan to launch them soon in India. The company has also acquired a facility in Mehsana for this and expects commercial operations at the plant to begin from March 2022, Lincoln Pharmaceuticals said in a regulatory filing.

The factory will supply all cephalosporin products such as tablets, capsules, dry syrup and injectables. The company plans to start registering its products for the domestic and export markets soon, he added.

“The entire expansion of Cephalosporin products will be funded by internal provisions. The company has earmarked a total investment of approximately Rs 30 crore for this expansion,” said Lincoln Pharmaceuticals chief executive Mahendra Patel.

The company plans to manufacture more than 20 cephalosporin products, including cefalexin BP oral suspension, clavulanate tablets, cefixime capsules, cefuroxime axetil tablets, among others, according to the filing.

It plans to export the products to markets in Africa, Latin America and Southeast Asia, he added.

“Cephalosporin is a broad-spectrum bactericidal, P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infections, angina strep throat, staph infections, tonsillitis, bronchitis and the like, “the record says.

Lincoln Pharma shares were trading at Rs 386.80 per certificate on BSE, up 1.10% from its previous close.

Source link

Leave A Reply

Your email address will not be published.